ByShankar N:OverviewAmgen, Inc. (AMGN) incorporated in 1980 is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Headquartered in Thousand Oaks Ca

In a report published Wednesday, Goldman Sachs analyst Terence Flynn reiterated a Buy rating and $130.00 price target on Amgen (NASDAQ: AMGN).

Amgen Inc. (AMGN)UBS Global Healthcare Conference CallMay 21, 2013 10:00 a.m. ETExecutivesJoseph P. Miletich - Senior Vice President of Research and DevelopmentAnalystsMatthew Roden - UBSPresentationMarc Goodman - UBSGood morning, everyone. My name i

A new first-of-its-kind immunotherapy trains the immune system to target cancer cells. Can it revolutionize cancer treatment for good?

ByStephen Barnes:Amgen (AMGN) shares (up over 22% year-to-date) have had an impressive run this year, outpacing the S&P 500 by about 6%. Nevertheless, despite outpacing the broader market, Amgen has only matched the Health Care Sector Select Sector S

A coffee shop's rude sign dissing one of the biggest bike races in the U.S. has incensed the cycling community.  A source sent us a photo of the sign, which was posted at Joe Momma's Coffee in Avila Beach, California ahead of the Amgen Tour

As some firms want to make and sell drugs similar to biological medicines made by the likes of Amgen and Genentech, a measure aims to regulate their use.SACRAMENTO — Two of the nation's largest biotech companies — Amgen Inc. of Thousand O

Looking at the universe of stocks we cover at Dividend Channel, on 5/14/13, Amgen Inc (NASD: AMGN) will trade ex-dividend, for its quarterly dividend of $0.47, payable on 6/7/13. As a percentage of AMGN's recent stock price of $104.54, this divi

Amgen (NASDAQ: AMGN) and Zhejiang Beta Pharma Co., Ltd.(Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in the Chinese market. Together, Amgen

By EXPstocktrader:Rewind to 2012, Affymax (AFFY) was a favorite and top performing biotech stock for 2012. The company had in its pipeline a new drug that was supposed to break the huge multi-billion dollar monopoly that Amgen (AMGN) had in the diabe

Transgenomic, Inc. (OTC: TBIO) today announced that it hasentered into a collaboration with Amgen Inc. (NASDAQ: AMGN) to develop aCE-IVD test to screen patients with metastatic colorectal cancer (mCRC)for RAS mutations (KRAS and NRAS).

The company: Amgen Inc.    

Biotechnology firm Amgen recently falls short of first-quarter sales targets but is confident many of the drugs it has in development will be approved.Amgen Inc. is a biotechnology company that develops medicines used in the treatment of cancer, kidn

By Peter Geschek:For the past two and a half decades Amgen (AMGN) and Johnson & Johnson (JNJ) had the US Epogen market divided up among themselves: Amgen marketing the recombinant human erythropoietin primarily to dialysis patients and Johnson & John

May 1 (Reuters) - Drugs from Amgen Inc, TevaPharmaceutical Industries and Sanofi thatboost white blood cells are being evaluated by U.S. regulatorsas treatments for radiation exposure caused by a nuclear attackor accident.

May 1 (Reuters) - Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.

As a big biotech, Amgen is driven by sales and pipeline news.

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the first two weeks of April.The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ:

By Peter Geschek:EnbrelEnbrel, co-promoted by Amgen (AMGN) and Pfizer (PFE) is one of the most successful drugs in history. Amgen sells it in the U.S. and Canada, Pfizer sells it to the rest of the world. In 2012, Enbrel was the world's second best-s

First-quarter sales climb 5% for the biotech giant, which is looking to develop a host of new drugs.Shares of biotech giant Amgen Inc. slumped as investors reacted to weaker-than-expected first-quarter sales.    

In a report published Wednesday, Piper Jaffray analyst M.

BOSTON (TheStreet) -- Sell-side analysts have been jumping over each other to upgrade and raise price targets on almost all biotech stocks in a desperate attempt to stay ahead of the raging bull market that has pushed large-cap biotech stocks to reco

With biotech stocks trading at all-time highs, the fear is that generalist investors will sell at first sign of trouble. Click to view a price quote on AMGN. Click to research the Drugs industry.    

April 23 (Reuters) - Amgen Inc on Tuesday reported first-quarter sales that fell short of Wall Street expectations for most of its biggest-selling medicines, and its shares fell more than 6 percent.

April 23 (Reuters) - Amgen Inc on Tuesday reportedfirst-quarter sales that fell short of Wall Street expectationsfor most of its biggest-selling medicines, and its shares fellmore than 6 percent.

April 23 (Reuters) - Amgen Inc on Tuesday reported first-quarter sales that fell short of Wall Street expectations for most of its biggest-selling medicines, and its shares fell more than 6 percent.

April 23 (Reuters) - Amgen Inc on Tuesday reported first-quarter sales that fell short of Wall Street expectations for most of its biggest-selling medicines, and its shares fell more than 6 percent.

THOUSAND OAKS, Calif. (TheStreet) -- Amgenposted adjusted earnings for the first quarter that grew 22% and beat Street expectations. However, Amgen's bottom-line beat was driven largely by tax benefits and fewer outstanding shares but not revenue, wh

Here's your Cheat Sheet to earnings...

April 23 (Reuters) - Amgen Inc on Tuesday reported higher first-quarter profit on increased sales of its drug Enbrel for rheumatoid arthritis and newer medicines to help prevent bone fractures.

April 23 (Reuters) - Amgen Inc on Tuesday reportedhigher first-quarter profit on increased sales of its drugEnbrel for rheumatoid arthritis and newer medicines to helpprevent bone fractures.

By WhisperNumber: Amgen Inc. (AMGN) is expected to report fiscal first quarter earnings on Tuesday, April 23rd. The whisper number is $1.90, six cents ahead of the analysts' estimate. AMGN has a 59% positive surprise history (having topped the whispe

Here's your Cheat Sheet to earnings...

Amgen (NYSE: AMGN), shares of which reached a multiyear high Monday, is scheduled to report its first-quarter 2013 results Tuesday, April 23, after the markets close.Investors will be keeping an eye on the impact that a recent German regulatory revie

The premier biotech has been hitting all-time record highs.

(The following statement was released by the rating agency) CHICAGO, April 19 (Fitch) Fitch Ratings has affirmed Amgen Inc.'s (Amgen) ratings, including the Issuer Default Rating (IDR) at 'BBB'. The Rating Outlook is Stable. A full list of ratings af

FRANKFURT, April 18 (Reuters) - Drugs from Novo Nordisk , Amgen, Bayer and other companies could face price cuts in Germany as the country's medical cost-benefit agency widens a review into the value offered by medicines.

(Reuters) - Amgen Inc has agreed to pay $24.9 million to settle allegations that it provided kickbacks to long-term care pharmacy providers to entice them to use its Aranesp anemia drug instead of a rival medicine, the Department of Justice announced

Amgen Inc has agreed to pay $24.

April 16 (Reuters) - Amgen Inc has agreed to pay $24.9 million to settle allegations that it provided kickbacks to long-term care pharmacy providers to entice them to use its Aranesp anemia drug instead of a rival medicine, the U.S. Department of Jus

April 16 (Reuters) - Amgen Inc has agreed to pay $24.9 million to settle allegations that it provided kickbacks to long-term care pharmacy providers to entice them to use its Aranesp anemia drug instead of a rival medicine, the U.S. Department of Jus

By Peter Geschek:Apremilast, Celgene's (CELG) experimental drug for psoriasis, in a Phase 3 trial showed good safety profile, but its efficacy was similar to Amgen's (AMGN) Enbrel, and inferior to AbbVie's (ABBV) Humira and Johnson & Johnson's (JNJ)

The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of March.The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Arena Pharmaceuticals (NASDAQ: ARNA), Illumina (NASDAQ:

Amgen Inc.'s new chief executive, Robert A. Bradway, received total compensation of $13.6 million in 2012, more than his predecessor, according to an analysis of a company regulatory filing.

By Osman Gulseven:Amgen (AMGN) is among the hottest large-cap biotech stocks of this year. The stock has been following an upward trend since last April. Most recently, it rallied past the previous 52-week highs. After this run, the stock even surpas

By Bio Vantage:The stock price of Amgen (AMGN) has advanced from $85 in January to $102 (as of March 28), a decent 20% increase in just three months. The question in an investor's mind is: Will this run continue? How much is AMGN really worth? In our

By Bio Vantage:The stock price of Amgen (AMGN) has advanced from $88 to $102 since we covered it last November (Amgen: Equity Report And Stock Valuation). This translates to a decent 16% increase in just four months. In that report, we had derived a

The four horsemen of the biotechnology – Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB), Celgene (NASDAQ: CELG) and Gilead Sciences (NASDAQ: